pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,620 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive241onclive165Fierce Biotech91BioSpace90raps32globenewswire health28fda recalls
therapy area
allOncology574Rare Disease284Immunology229Cardiology193Hematology159Pulmonology131Vaccines99Psychiatry & CNS
  • PCOS’s new name is PMOS, a small letter change that required a big scientific process
    A revised name for PCOS — polyendocrine metabolic ovarian syndrome, or PMOS — was introduced in a paper published Tuesday.
    STAT · 2mo ago↗ source
  • STAT+: Despite its toll, alcohol is still an awkward subject in the doctor’s office
    Alcohol screening and counseling are too often compressed or skipped during doctor's visits — a gap that is costing patients and the health care system.
    STAT · 2mo ago↗ source
  • STAT+: Alcohol is wreaking havoc on U.S. public health. American society looks the other way
    The Deadliest Drug, a new investigative series, shows that the alcohol epidemic is a generational failure of the medical and public health systems, of industry, and of government.
← prev
page 49 of 65
next →
22
fda press21
fda medwatch17
87
Ophthalmology86
Pain75
Endocrinology & Metabolism52
Dermatology51
STAT · 2mo ago
↗ source
  • 6 takeaways from STAT’s investigation into the U.S. alcohol epidemic
    Alcohol is the culprit behind the United States' most enduring and overlooked drug crisis. Here are 6 takeaways from STAT's new investigative series, The Deadliest Drug.
    STAT · 2mo ago↗ source
  • Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
    American biotech leaders are destroying their own industry.
    STAT · 2mo ago↗ source
  • STAT+: Patients jockey for exemptions from Medicaid’s new work requirements
    Advocates for people with HIV and sickle cell disease are among those pushing for exemptions from Medicaid’s new work requirements.
    STAT · 2mo ago↗ source
  • STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
    Bristol Myers Squibb and China's Hengrui Pharma are teaming up to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion.
    STAT · 2mo ago↗ source
  • Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL
    Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.
    onclive · 2mo ago↗ source
  • Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
    Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
    onclive · 2mo ago↗ source
  • Supreme Court temporarily extends women’s access to a widely used abortion pill
    The Supreme Court is temporarily extending access to a widely used abortion pill while it considers whether to allow restrictions on the drug to take effect.
    STAT · 2mo ago↗ source
  • Optum Rx unveils pharmacy model with clear fees, building on transparency push
    UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said offers its customers transparency into the entire drug supply chain. Under the new model,…
    Endpoints · 2mo ago↗ source
  • STAT+: Colombia wins a key court ruling over a compulsory license issued for an HIV medicine
    A South American court upheld the steps taken by the Colombian government when it issued a compulsory license two years ago for an HIV medicine.
    STAT · 2mo ago↗ source
  • Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL
    Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.
    onclive · 2mo ago↗ source
  • Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
    It seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it wou…
    Endpoints · 2mo ago↗ source
  • STAT+: Trump pivots on kratom derivative 7-OH, floating approval for some forms
    Last year, the FDA had warned that natural opioids in kratom were being turned into harmful products. Now President Trump says approval should be considered.
    STAT · 2mo ago↗ source
  • STAT+: Medicare’s miss on Alzheimer’s drug spending
    Far fewer seniors than expected are taking costly Alzheimer's drugs.
    STAT · 2mo ago↗ source
  • No FDA permission, no problem: New flavored vape policy worries experts
    A new FDA policy will let some flavored vapes stay on the market without authorization.
    STAT · 2mo ago↗ source
  • MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
    Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.
    onclive · 2mo ago↗ source
  • INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC
    First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.
    onclive · 2mo ago↗ source
  • Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
    Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a new five-year business plan on Monday ...
    Endpoints · 2mo ago↗ source
  • New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China
    Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial: 🧠 Novo's Parkinson's cell therapy finds a biotech home: Novo Nordisk has found a home for an…
    Endpoints · 2mo ago↗ source
  • Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone
    San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more t…
    Endpoints · 2mo ago↗ source
  • Treatment Intensification Gains Momentum in mCSPC Management
    During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.
    onclive · 2mo ago↗ source
  • STAT+: Astellas treatment offers new hope to a devastated rare disease community
    Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations
    Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.
    onclive · 2mo ago↗ source